| Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study C Darryl, E Bertini, KJ Swoboda, WL Hwu, TO Crawford, RS Finkel, ... Neuromuscular Disorders 29 (11), 842-856, 2019 | 611 | 2019 |
| Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial CM McDonald, C Campbell, RE Torricelli, RS Finkel, KM Flanigan, ... The Lancet 390 (10101), 1489-1498, 2017 | 480 | 2017 |
| New genetic loci that control susceptibility and symptoms of experimental allergic encephalomyelitis in inbred mice RJ Butterfield, JD Sudweeks, EP Blankenhorn, R Korngold, JC Marini, ... The Journal of Immunology 161 (4), 1860-1867, 1998 | 186 | 1998 |
| Population-based prevalence of myotonic dystrophy type 1 using genetic analysis of statewide blood screening program NE Johnson, RJ Butterfield, K Mayne, T Newcomb, C Imburgia, D Dunn, ... Neurology 96 (7), e1045-e1053, 2021 | 137 | 2021 |
| Genetic analysis of disease subtypes and sexual dimorphisms in mouse experimental allergic encephalomyelitis (EAE): relapsing/remitting and monophasic remitting/nonrelapsing … RJ Butterfield, EP Blankenhorn, RJ Roper, JF Zachary, RW Doerge, ... The Journal of Immunology 162 (5), 3096-3102, 1999 | 128 | 1999 |
| Identification of genetic loci controlling the characteristics and severity of brain and spinal cord lesions in experimental allergic encephalomyelitis RJ Butterfield, EP Blankenhorn, RJ Roper, JF Zachary, RW Doerge, ... The American journal of pathology 157 (2), 637-645, 2000 | 120 | 2000 |
| Position of Glycine Substitutions in the Triple Helix of COL6A1, COL6A2, and COL6A3 is Correlated with Severity and Mode of Inheritance in Collagen VI … RJ Butterfield, AR Foley, J Dastgir, S Asman, DM Dunn, Y Zou, Y Hu, ... Human mutation 34 (11), 1558-1567, 2013 | 103 | 2013 |
| Effect of different corticosteroid dosing regimens on clinical outcomes in boys with Duchenne muscular dystrophy: a randomized clinical trial M Guglieri, K Bushby, MP McDermott, KA Hart, R Tawil, WB Martens, ... Jama 327 (15), 1456-1468, 2022 | 101 | 2022 |
| Gender, age, and season at immunization uniquely influence the genetic control of susceptibility to histopathological lesions and clinical signs of experimental allergic … C Teuscher, JY Bunn, PD Fillmore, RJ Butterfield, JF Zachary, ... The American journal of pathology 165 (5), 1593-1602, 2004 | 100 | 2004 |
| Genetic analysis of the influence of pertussis toxin on experimental allergic encephalomyelitis susceptibility: an environmental agent can override genetic checkpoints EP Blankenhorn, RJ Butterfield, R Rigby, L Cort, D Giambrone, ... The Journal of Immunology 164 (6), 3420-3425, 2000 | 90 | 2000 |
| Sequence polymorphisms in the chemokines Scya1 (TCA-3), Scya2 (monocyte chemoattractant protein (MCP)-1), and Scya12 (MCP-5) are candidates for eae7, a locus controlling … C Teuscher, RJ Butterfield, RZ Ma, JF Zachary, RW Doerge, ... The Journal of Immunology 163 (4), 2262-2266, 1999 | 89 | 1999 |
| Whole-genome analysis for effective clinical diagnosis and gene discovery in early infantile epileptic encephalopathy BEP Ostrander, RJ Butterfield, BS Pedersen, AJ Farrell, RM Layer, ... NPJ genomic medicine 3 (1), 22, 2018 | 87 | 2018 |
| The care of patients with Duchenne, Becker, and other muscular dystrophies in the COVID‐19 pandemic A Veerapandiyan, KR Wagner, S Apkon, CM McDonald, KD Mathews, ... Muscle & Nerve 62 (1), 41-45, 2020 | 81 | 2020 |
| Genetic control of susceptibility to experimental Lyme arthritis is polygenic and exhibits consistent linkage to multiple loci on chromosome 5 in four independent mouse crosses RJ Roper, JJ Weis, BA McCracken, CB Green, Y Ma, KS Weber, ... Genes & Immunity 2 (7), 388-397, 2001 | 81 | 2001 |
| p53 convergently activates Dux/DUX4 in embryonic stem cells and in facioscapulohumeral muscular dystrophy cell models EJ Grow, BD Weaver, CM Smith, J Guo, P Stein, SC Shadle, ... Nature genetics 53 (8), 1207-1220, 2021 | 78 | 2021 |
| Developing standardized corticosteroid treatment for Duchenne muscular dystrophy M Guglieri, K Bushby, MP McDermott, KA Hart, R Tawil, WB Martens, ... Contemporary clinical trials 58, 34-39, 2017 | 77 | 2017 |
| Association study of exon variants in the NF-κB and TGFβ pathways identifies CD40 as a modifier of Duchenne muscular dystrophy L Bello, KM Flanigan, RB Weiss, DM Dunn, KJ Swoboda, E Gappmaier, ... The American Journal of Human Genetics 99 (5), 1163-1171, 2016 | 75 | 2016 |
| Congenital muscular dystrophy and congenital myopathy RJ Butterfield CONTINUUM: Lifelong Learning in Neurology 25 (6), 1640-1661, 2019 | 68 | 2019 |
| Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 … CM McDonald, E Marbán, S Hendrix, N Hogan, RR Smith, M Eagle, ... The Lancet 399 (10329), 1049-1058, 2022 | 67 | 2022 |
| Congenital lethal motor neuron disease with a novel defect in ribosome biogenesis RJ Butterfield, TJ Stevenson, L Xing, TM Newcomb, B Nelson, W Zeng, ... Neurology 82 (15), 1322-1330, 2014 | 65 | 2014 |
